Financial Performance - In 2024, Jiangsu Wuzhong achieved a consolidated net profit of ¥70,483,471.07, while the parent company's net profit was ¥39,864,975.54[7]. - The parent company reported an initial undistributed profit of -¥910,780,011.15 at the beginning of the year, ending with -¥870,915,035.61, resulting in no profit distribution for 2024[7]. - The company's operating revenue for 2024 was approximately ¥1.60 billion, a decrease of 28.64% compared to ¥2.24 billion in 2023[29]. - The net profit attributable to shareholders was ¥70.48 million, recovering from a loss of ¥71.95 million in the previous year[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51.27 million, compared to a loss of ¥98.88 million in 2023[29]. - The weighted average return on equity increased to 3.95%, up by 8.01 percentage points from -4.06% in 2023[29]. - The total assets decreased by 8.14% to approximately ¥3.97 billion from ¥4.33 billion in 2023[29]. - The company achieved operating revenue of CNY 1,598.51 million, a decrease of 28.64% compared to the previous year, with main business revenue down by 28.97%[97]. - Gross profit reached CNY 772.58 million, an increase of 42.12% year-on-year, with main business gross profit up by 43.46%[97]. - The company reported a significant increase in other income, up 296.29% to CNY 18.40 million, primarily due to government subsidies[98]. Legal and Regulatory Issues - The company is facing legal challenges, including a lawsuit against its wholly-owned subsidiary for alleged involvement in tax fraud, with the first court hearing held on April 22, 2025[12]. - The company is under scrutiny from the China Securities Regulatory Commission due to the overdue debts and potential legal implications[12]. - Jiangsu Wuzhong's financial report received an audit opinion of "unable to express" from Zhongxing Caiguanghua Accounting Firm, indicating potential concerns regarding financial accuracy[6]. Research and Development - The company has established a strict project management system for R&D, enhancing progress, quality, and procedural improvements to ensure the integrity and authenticity of R&D data[44]. - The company is actively exploring equity cooperation models and CDMO partnerships to address raw material supply constraints and expand its production capabilities[45]. - The company achieved a 100% pass rate in inspections by various drug regulatory authorities, ensuring stable production and quality management[47]. - The company is leveraging AI-driven protein design technology to shorten the development cycle of recombinant collagen, enhancing its R&D capabilities in this field[53]. - Total R&D investment amounted to ¥91,580,022.07, representing 5.73% of total operating revenue[107]. - The number of R&D personnel is 128, making up 11.7% of the total workforce[108]. - Research and development expenses increased by 55.63% to CNY 61.12 million, reflecting a focus on enhancing internal R&D capabilities[98]. Market and Product Development - The company reported a significant increase in sales from its medical beauty sector, particularly the AestheFill product, which started sales in April 2024[28]. - The company’s AestheFill product, a high-end injection for aesthetic medicine, received market approval in January 2024, with a sales team of 55 people covering 537 medical institutions by the end of 2024[50]. - AestheFill holds a nearly 30% market share in the aesthetic regenerative injection market in Taiwan, with a higher price range than similar products[49]. - The company is focusing on non-surgical aesthetic biotechnology and expanding its product pipeline in the dermal filler market, which is experiencing rapid growth due to increasing consumer acceptance[62]. - The company is actively developing new products, with three Class II medical devices receiving registration certificates from Jiangsu Provincial Drug Administration by December 2024[94]. - The company is pursuing a dual-driven strategy of self-research and external investment to expand its medical beauty product portfolio[96]. Financial Management and Governance - The company has established a comprehensive investor relations management system, enhancing communication with investors through multiple channels[182]. - The company held 9 board meetings during the reporting period, with all resolutions passed[181]. - The total pre-tax remuneration for the board members and senior management amounted to 637.54 million CNY[189]. - The company has been proactive in addressing investor feedback and suggestions to strengthen trust and transparency[182]. - The company has scheduled additional extraordinary shareholder meetings to address various governance and operational matters throughout 2024[184][188]. - The company is committed to maintaining high standards of corporate governance and compliance with regulatory requirements[192]. Industry Trends and Challenges - The pharmaceutical industry is experiencing significant challenges, with overall valuation and performance declining due to factors such as trade tensions and increased competition, yet it shows resilience through innovation and policy support[156]. - The medical beauty industry is entering a "strong regulation" era, with new policies aimed at protecting consumer rights and ensuring industry standards[79]. - The overall pharmaceutical market is expected to maintain steady growth driven by factors such as aging population and increasing income levels, supported by ongoing healthcare reforms[158]. - The light medical beauty sector is projected to grow at a CAGR of 17.5% from 2021 to 2030, significantly outpacing the surgical segment's 10.4% growth rate[159].

江苏吴中医药发展股份有限公司 第十一届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）第十一届监事会第四 次会议通知于 2025 年 4 月 18 日以书面或电子邮件等形式发出，会议于 2025 年 4 月 29 日在公司会议室举行。会议应到监事 3 人，实到监事 3 人。会议的召开 符合《公司法》和相关法律法规以及《公司章程》《监事会议事规则》的有关规 定。会议由监事会主席吴振邦先生主持，会议经过审议，以书面投票表决方式通 过了如下决议： 一、审议通过了江苏吴中医药发展股份有限公司 2024 年度监事会工作报告 表决结果：3 票同意， 0 票弃权， 0 票反对。 本议案尚需提交公司股东大会审议通过。 二、审议通过了江苏吴中医药发展股份有限公司 2024 年度报告与年报摘要 监事会经审议后认为：公司 2024 年度报告及年报摘要的编制和审议程序符 合《公司法》《上海证券交易所股票上市规则》等法律法规及《公司章程》等规 章制度的要求；年报内容和格式符合《公 ...

公司监事会将依法履行监督职责，持续关注董事会和管理层相关工作的开展， 切实维护公司及全体股东的合法权益。 江苏吴中医药发展股份有限公司 监事会 2025 年 4 月 30 日 江苏吴中医药发展股份有限公司监事会对 《董事会关于 2024 年度无法表示意见的财务报告审计 报告和内部控制审计报告的专项说明》的意见 中兴财光华会计师事务所（特殊普通合伙）对江苏吴中医药发展股份有限公 司（以下简称"公司"或"江苏吴中"）2024 年度财务报表进行了审计，并出 具了无法表示意见的审计报告。根据中国证券监督管理委员会《公开发行证券的 公司信息披露编报规则第 14 号——非标准审计意见及其涉及事项的处理》和《上 海证券交易所股票上市规则》的要求，公司监事会对董事会就会计师事务所对公 司 2024 年度财务报告无法表示意见的财务报告审计报告和内部控制审计报告的 专项说明出具如下意见： 监事会认为：中兴财光华会计师事务所出具的无法表示意见的财务报告审计 报告和内部控制审计报告客观地反映了公司 2024 年度的财务状况和经营情况， 监事会对无法表示意见审计报告无异议。公司董事会对无法表示意见审计报告的 专项说明符合公司的实际情况 ...

江苏吴中（600200）公告，2025年第一季度营收为3.17亿元，同比下降25.44%；净亏损7031.79万元， 去年同期净利润505.91万元。 ...

江苏吴中：公司股票将被实施退市风险警示及其他风险警示 智通财经4月29日电，江苏吴中(600200.SH)公告称，由于中兴财光华会计师事务所对公司2024年度财务 报告出具了无法表示意见的审计报告，公司股票将被实施退市风险警示。同时，由于该事务所对公司 2024年度出具了无法表示意见的内部控制审计报告，公司股票还将被实施其他风险警示。公司股票将于 2025年4月30日停牌一天，自2025年5月6日起被实施退市风险警示，股票简称将变更为*ST苏吴。实施 退市风险警示后，公司股票将在风险警示板交易，日涨跌幅限制为5%。 ...

New Stock Offerings - ST Xinchao (600777) has two tender offer periods: April 8 to May 7, 2025, and April 23 to May 22, 2025[1] - Puli Tui (300630) is in the delisting arrangement period with 13 trading days remaining[1] - ST Yushun (002289) and ST Jingan (600190) are also highlighted for their recent announcements[1] Market Alerts - Jinlitai (300225) has been flagged for severe abnormal fluctuations[1] - Guoguang Chain (605188) and Dongfang Tong (300379) have recent announcements regarding their trading status[1] - Multiple stocks including Huadian Energy (600726) and Huadian Liaoning (600396) have recent updates as of April 29, 2025[1] Trading Periods - The last trading day for several stocks is approaching, with specific mention of ST Yushun and ST Jingan[1] - The report indicates that various stocks are under observation due to unusual trading activities[2]

证券代码：600200 证券简称：江苏吴中 公告编号：临2025-020 江苏吴中医药发展股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日、4 月 25 日、4 月 28 日股票交易连续三个交易日内收盘价格跌幅偏离值累 计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常 波动的情形。 公司被立案调查，存在重大违法强制退市风险。公司已被中国证券监督 管理委员会(以下简称"中国证监会")立案调查，若后续经中国证监会行政处罚 认定的事实，触及《上海证券交易所股票上市规则》规定的重大违法强制退市情 形，即使公司 2024 年实现盈利，公司股票也将被实施重大违法强制退市。 公司 2024 年度财务报告不排除被出具无法表示意见的审计报告。目前， 公司正积极与审计机构保持沟通并补充材料，努力配合审计机构审计工作，尽最 大努力消除影响审计意见类型的风险事项，最终审计意见类型须以审计机构正式 出具的审计 ...

(签字页见下) (本页无正文,为致江苏吴中医药发展股份有限公司的回复函的签字页) 实际控制人: 致江苏吴中医药发展股份有限公司的回复函 江苏吴中医药发展股份有限公司: 你公司函悉。经核查,截至目前,除已披露信息外,不存在影响上市公司 股票交易价格异常波动的重大信息,不存在应披露而未披露的重大信息,包括 但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥离、 资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战略投资者 等重大事项。 特此回复。 2025 年 4 月 28 日 钱群英 ...

苏州吴中 你公司函悉。经我公司核查,截至目前,除已披露信息外,不存在影响上 市公司股票交易价格异常波动的重大信息，不存在应披露而未披露的重大信息, 包括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥 离、资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战略投 资者等重大事项。 特此回复。 致江苏吴中医药发展股份有限公司的回复函 江苏吴中医药发展股份有限公司: ...

Core Viewpoint - Jiangsu Wuzhong has faced significant challenges due to allegations of information disclosure violations and financial irregularities, leading to a sharp decline in stock price and potential risks of forced delisting, despite recent profitability in its aesthetic medicine segment [1][3][12]. Financial Performance - Jiangsu Wuzhong reported revenues of 2.026 billion yuan and 2.240 billion yuan for 2022 and 2023, respectively, with net losses of 76.27 million yuan and 71.95 million yuan [1]. - The company forecasts a turnaround in 2024, expecting a net profit of 55 million to 80 million yuan, driven by its aesthetic medicine product AestheFill [1][12]. Aesthetic Medicine Segment - Since 2021, Jiangsu Wuzhong has intensified its focus on the aesthetic medicine sector, which has become a key growth driver [2][11]. - AestheFill, launched in April 2024, is projected to significantly contribute to revenue, with expectations of generating approximately 350 million yuan in 2024 [12][13]. Regulatory and Legal Issues - The company has been under investigation by the China Securities Regulatory Commission (CSRC) for alleged information disclosure violations since February 2023, which has led to a stock price drop of over 50% [3][5]. - Jiangsu Wuzhong's subsidiary is facing criminal charges related to tax fraud, further complicating the company's legal landscape [6][7]. Financial Health Concerns - The company has exhibited a "high debt, high cash" situation, with cash holdings of 1.713 billion yuan and total borrowings of 1.71 billion yuan, raising concerns about financial management [3][4]. - As of the end of 2024, the company reported cash reserves of 1.412 billion yuan, indicating ongoing financial strain [4]. Market Outlook - The aesthetic medicine market in China is expected to grow rapidly, with projections indicating a market size of 11.52 billion yuan by 2027, driven by a compound annual growth rate of 54.73% from 2021 to 2025 [13]. - Despite the competitive landscape, Jiangsu Wuzhong's strategic investments in aesthetic medicine may position it for future growth, contingent on resolving current legal and regulatory challenges [12][13].